Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. partners with Mölnlycke Health Care to combat healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) by distributing their Steriwave nasal decolonization technology across the UK, EU, and Middle East. The technology, which is a non-antibiotic, light-activated therapy, has been clinically proven to reduce pathogens responsible for HAIs without contributing to AMR. The partnership aims to integrate Steriwave into Mölnlycke’s infection control portfolio and is set to begin in the UK in Q4 2024, with plans to expand into additional markets in 2025.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
